Goldman Sparks Surge In Revolution Medicines Shares

Revolution Medicines (RVMD) received FDA Breakthrough Therapy Designation for its cancer treatment, boosting its profile. The stock has surged 152.92% year-to-date, with analysts valuing it at $251.21, above its current $199.86. The company's pipeline includes eight Phase III trials, with potential long-term revenue growth if successful.

Revolution Medicines (RVMD) received FDA breakthrough designation for RASONQUE, a pancreatic cancer drug. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX has risen 60% in a year, providing diversified risk.

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

Revolution Medicines (RVMD) rose 4.8% after Goldman Sachs initiated coverage with a Buy rating, citing confidence in its oncology platform. The FDA granted Breakthrough Therapy Designation to RASONQUE for pancreatic cancer, reinforcing regulatory momentum. Recent U.S. approval of RASONQUE also supports the stock's transition to a commercial-stage company.

Goldman Sachs resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $267 price target. The company, trading at a high P/S ratio, is unprofitable but has a strong balance sheet. Insiders have sold shares, while some gurus have increased holdings. RVMD's GF Score is 25/100, indicating financial challenges.

Revolution Medicines (RVMD) received FDA Breakthrough Therapy designation for its drug RASONQUE. The article discusses analyst projections and long-term expectations for the company, based on historical data and forecasts. Simply Wall St notes it does not provide financial advice and has no position in RVMD.